PTAC recommended the listing of Perjeta (pertuzumab) for patients with metastatic breast cancer

At its meeting on 13-14 February 2014, the Committee reviewed an application from Roche for the funding of pertuzumab (Perjeta) ...

Read more →

NICE issues final draft guidance recommending enzalutamide for prostate cancer

People with hormone-relapsed prostate cancer that has spread to other parts of the body and have been treated with the ...

Read more →